DrugPatentWatch Database Preview
NUVARING Drug Profile
Which patents cover Nuvaring, and when can generic versions of Nuvaring launch?
Nuvaring is a drug marketed by Organon Sub Merck and is included in one NDA.
The generic ingredient in NUVARING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.
Summary for NUVARING
Recent Clinical Trials for NUVARING
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 4 |
| University of Washington | Phase 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
Recent Litigation for NUVARING
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Merck Sharp & Dohme B v. v. Dr. Reddy's Laboratories, S.A. | 2015-09-11 |
| Merck Sharp & Dohme B v. v. Warner Chilcott Company LLC | 2013-12-24 |
Pharmacology for NUVARING
| Drug Class | Progestin Estrogen |
| Mechanism of Action | Estrogen Receptor Agonists |
Synonyms for NUVARING
| 131562-74-8 |
| 135988-10-2 |
| 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17alpha)-, mixt. with (17alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol |
| Ethinyl estradiol and etonogestrel |
| Ethinylestradiol mixture with etonogestrel |
| Ethinylestradiol-3-oxodesogestrel mixt. |
| Etonogestrel and ethinyl estradiol |
| Etonogestrel-ethynylestradiol mixt. |
| Etonogestrel/Ethinyl Estradiol Vaginal Ring |
| LS-187950 |
| SCHEMBL20544194 |
Paragraph IV (Patent) Challenges for NUVARING
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| NUVARING | RING;VAGINAL | ethinyl estradiol; etonogestrel | 021187 | 2013-06-17 |
US Patents and Regulatory Information for NUVARING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Sub Merck | NUVARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 021187-001 | Oct 3, 2001 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NUVARING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Organon Sub Merck | NUVARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 021187-001 | Oct 3, 2001 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
